T Cell Lymphomas
LA JOLLA, CALIF. – The phase 1 study tested the addition of a histone deacetylase inhibitor to platinum-based chemotherapy.
LA JOLLA, CALIF. – Investigators said that prolonged treatment with the drug does not appear to pose an increased safety risk.
LA JOLLA, CALIF. – Chidamide produced a higher response rate in relapsed/refractory PTCL patients than what was observed in a prior phase 2 trial...
LA JOLLA, CALIF. – New developments include using epigenetic therapy to enhance immune checkpoint therapy and using epigenetic-based combination...
LA JOLLA, CALIF. – Registry data have influenced the treatment of patients with PTCL in the Czech Republic.
SAN DIEGO – The newly approved regimen outperformed the standard CHOP regimen in this rare cancer.
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
DUBROVNIK, CROATIA – Dr. Ali Bazarbachi gives his tips for when to use allo- versus auto-HSCT in patients with peripheral T-cell lymphomas.
From the Journals
The small study showed high response and no significant safety concerns.
Takeda Pharmaceuticals and Seattle Genetics announced phase 3 trial results in frontline treatment of peripheral T-cell lyphoma (PTCL).
The partial hold that paused U.S.-based enrollment in clinical trials of tazemetostat has been lifted.